Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.

Employees

638

Sector

Biotechnology & Medical Research

Calendar

20/09/2024 - TD Cowen Chronic Urticaria Summit

More about the company

Quotes

Date	Price	Change	Volume
19/09/24	91.77 $	+2.73%	286,859
18/09/24	89.33 $	+3.26%	921,804
17/09/24	86.51 $	+0.24%	714,024
16/09/24	86.30 $	-2.92%	536,658
13/09/24	88.90 $	+5.71%	617,619

Delayed Quote Nasdaq, September 19, 2024 at 06:33 pm

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

89.33USD

Average target price

127.35USD

Spread / Average Target

+42.56%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 18:51:09 19/09/2024 BST			5-day change	1st Jan Change
91.88 ^USD	+2.86%		+9.12%	-0.51%

09-05	Blueprint Medicines Corporation Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 01:50 PM
08-07	Blueprint Medicines Insider Sold Shares Worth $3,905,872, According to a Recent SEC Filing	MT

Capitalization	5.66B 426B	P/E ratio 2024 *	-71.7x	P/E ratio 2025 *	-60.8x
Enterprise value	5.14B 387B	EV / Sales 2024 *	9.85x	EV / Sales 2025 *	7.11x
Free-Float	99.07%	Yield 2024 *	-	Yield 2025 *	0.56%

Blueprint Medicines Corporation Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 01:50 PM	09-05
Blueprint Medicines Insider Sold Shares Worth $3,905,872, According to a Recent SEC Filing	08-07	MT
Wedbush Adjusts Blueprint Medicines' Price Target to $129 From $120, Keeps Outperform Rating	08-01	MT
Blueprint Medicines Q2 Loss Narrows, Revenue Rises	08-01	MT
Blueprint Medicines Corporation, Q2 2024 Earnings Call, Aug 01, 2024	08-01
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q2 Revenue $138.2M, vs. Street Est of $103.9M	08-01	MT
Blueprint Medicines Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-01	CI
Blueprint Medicines Corporation Raises Revenue Guidance for the Full Year 2024	08-01	CI
Oppenheimer Adjusts Price Target on Blueprint Medicines to $125 From $114, Maintains Outperform Rating	07-08	MT
Voluntary Announcement - CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals Co., Ltd Enter into an Exclusive Promotion Agreement of AYVAKIT® (avapritinib tablets) in Mainland China	07-03	CI
Blueprint Medicines Insider Sold Shares Worth $7,713,537, According to a Recent SEC Filing	06-25	MT
CStone Gets Green Light for Local Manufacturing of AYVAKIT in China	06-13	MT
Blueprint Medicines Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM	06-10

Wedbush Adjusts Blueprint Medicines' Price Target to $129 From $120, Keeps Outperform Rating	08-01	MT
Oppenheimer Adjusts Price Target on Blueprint Medicines to $125 From $114, Maintains Outperform Rating	07-08	MT
Blueprint Medicines Insider Sold Shares Worth $7,713,537, According to a Recent SEC Filing	06-25	MT
Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing	06-07	MT
Blueprint Medicines Insider Sold Shares Worth $259,263, According to a Recent SEC Filing	06-05	MT

Blueprint Medicines Corporation Share Price

Equities

BPMC

US09627Y1091

Biotechnology & Medical Research

Valuation: Blueprint Medicines Corporation

Chart: Blueprint Medicines Corporation

Latest news: Blueprint Medicines Corporation

Last Transcript: Blueprint Medicines Corporation

Analysts' recommendations: Blueprint Medicines Corporation

Press Releases: Blueprint Medicines Corporation

News in other languages: Blueprint Medicines Corporation

Quotes and Performance

Course Extremes

Managers and Directors: Blueprint Medicines Corporation

ETFs: Blueprint Medicines Corporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

Blueprint Medicines to Present at Upcoming Investor Conferences	09-10	PR
Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT/AYVAKYT Full Year Revenue Guidance	08-02	AQ
Blueprint Medicines: Q2 Earnings Snapshot	08-01	AQ
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024	07-18	PR
CStone and Hengrui Enter into an Exclusive Promotion Agreement of AYVAKIT in Mainland China	07-04	AQ

Sanità : arriva in Italia un nuovo farmaco contro due malattie rare	02/03/23
USA-Les valeurs à suivre à Wall Street (actualisé)	10/02/23
Roche : autorisation conditionnelle pour Gavreto en Europe	19/11/21
Roche: Gavreto homologué en Europe contre le cancer du poumon	19/11/21
Roche: recommandation du CHMP pour Gavreto (pralsetinib)	17/09/21

1 day	+2.86%
1 week	+9.12%
Current month	-3.95%
1 month	-4.11%
3 months	-12.77%
6 months	+4.32%
Current year	-0.51%

Director	Title	Age	Since
Kathryn Haviland CEO	Chief Executive Officer	48	04/01/16
Michael Landsittel DFI	Director of Finance/CFO	52	31/08/14
Janet Loesberg CTO	Chief Tech/Sci/R&D Officer	61	29/02/20

Manager	Title	Age	Since
Alexis Borisy FOU	Founder	52	30/09/08
Nicholas Lydon FOU	Founder	67	30/09/08
Jeffrey Albers CHM	Chairman	52	23/07/14

Name	Weight	AuM	1st Jan change	Investor Rating
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	0.39%	0 M€	0.00%	-
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	0.24%	0 M€	0.00%	-
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD	0.18%	2 M€	-.--%

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
BLUEPRINT MEDICINES CORPORATION	+2.86%	+9.12%	+78.78%	-12.75%	5.48B
LONZA GROUP AG	+1.27%	-0.29%	+25.78%	-27.71%	45.62B
IQVIA HOLDINGS INC.	+1.39%	+3.13%	+17.70%	-2.89%	43.75B
ALNYLAM PHARMACEUTICALS, INC.	+1.07%	+5.61%	+57.36%	+50.67%	35.24B
CELLTRION, INC.	+3.23%	+5.66%	+37.64%	-22.41%	30.45B
MODERNA, INC.	-0.30%	-0.24%	-34.88%	-83.58%	27.67B
ICON PUBLIC LIMITED COMPANY	+0.68%	+1.52%	+15.57%	+13.22%	24.23B
UNITED THERAPEUTICS CORPORATION	+2.39%	+2.81%	+58.93%	+76.67%	15.35B
BIO-TECHNE CORPORATION	+5.29%	+9.71%	+13.70%	-39.26%	11.94B
MEDPACE HOLDINGS, INC.	+3.39%	+8.28%	+46.05%	+104.60%	10.97B
Average	+2.15%	+1.40%	+31.66%	+5.66%	25.07B
Weighted average by Cap.	+1.71%	+0.62%	+26.07%	-1.97%

	2024 *	2025 *
Net sales	496M 37.34B	687M 51.75B
Net income	-98.17M -7.39B	-117M -8.8B
Net Debt	-776M -58.45B	-776M -58.41B